Characterization of CD20 status in pre-mosunetuzumab tumor biopsy specimens by IHC. (A) Comparison of CD20 status determined by local CD20 staining per pathology reports vs central assessments using the dual CD20⁺PAX5⁺ IHC assay; shaded cells represent concordance between IHC assessments. (B) Percent CD20⁺PAX5⁺/PAX5⁺ cells in the tumor area before mosunetuzumab across NHL histologies from the GO29781 study. (C) CD20⁺PAX5⁺ staining relative to best overall response determined by investigator-assessed PET/CT imaging using the International Harmonization Project response criteria.³³ CT, computed tomography; ND, not determined; NE, not estimable; PD, progressive disease; PET, positron emission tomography; PR, partial response; SD, stable disease.